Cell Therapeutic Discovery Research
Make decisions preclinically, when comparing subtle gene edits in NK cell therapies1
Discover the true function of engineered cell products and the functional subsets that make a difference.
How our Award-Winning IsoLight Single-Cell System is Making a Difference
Solution
PSI™ revealed potency differences in gene edited NK cell therapies to enhance decision making
Finding
These critical potency differences between edited and wildtype cells also correlated with in vivo mouse response to therapy
Follow Our Data
See the latest published data in Cell Therapeutic Discovery Research
Polyfunctionality and PSI underscore significant differences between gene-edited KO- iPSC-NK cells and wild type cells. The CISH-/- knock- out cells showed enrichment of polyfunctional cell subsets compared to the wild type samples.
Similarly, the PSI of the knock-out cells is substantially (10x) higher than of the wild type (right) indicating that CIS plays a key role in regulating NK cell activation-induced exhaustion and that Notch activation prevents this exhaustion and enables production of functionally hyperactive NK cells. At day 35, CISH-/- iPSC-NK demonstrate better anti-tumor activity in vivo. These results are consistent with 10x higher in vitro PSI of CISH KO-iPSC-NK cells relative to wild type cells.1
[1] Reference: Zhu et al, ASH Annual Meeting 2018